# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Jonna Kim maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $15 to $25.
Piper Sandler analyst Korinne Wolfmeyer maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price tar...
https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds
https://www.usatoday.com/story/opinion/2024/07/02/biden-sanders-prescription-drug-cost-ozempic-wegovy/74232827007/
Hunterbrook releases a bearish report alleging that Hims & Hers sells knockoff GLP-1 weight loss drugs and relies on a sing...